



KFIN/CERT13(3)/MAR/2025 Date : April 9, 2025

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli, Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended March 31, 2025.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2025.

Description of Complaint	Opening Balance as on 01.01.2025	Received during the Period 01.01.2025 to 31.03.2025	Attended/Resolved during the Period 01.01.2025 to 31.03.2025	Pending as on 31.03.2025
Non-receipt of Dividend	NIL	03	03	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	01	01	NIL
SEBI	01	07	07	01
Stock Exchange	NIL	NIL	NIL	NIL
ODR	NIL	NIL	NIL	NIL
Total	01	11	11	01

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Limited

Rajitha Cholleti Vice President

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office:

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649